Richard A. Walgren

3.3k total citations
65 papers, 1.8k citations indexed

About

Richard A. Walgren is a scholar working on Genetics, Oncology and Hematology. According to data from OpenAlex, Richard A. Walgren has authored 65 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Genetics, 23 papers in Oncology and 21 papers in Hematology. Recurrent topics in Richard A. Walgren's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (12 papers), Chronic Myeloid Leukemia Treatments (11 papers) and Acute Myeloid Leukemia Research (9 papers). Richard A. Walgren is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (12 papers), Chronic Myeloid Leukemia Treatments (11 papers) and Acute Myeloid Leukemia Research (9 papers). Richard A. Walgren collaborates with scholars based in United States, United Kingdom and Japan. Richard A. Walgren's co-authors include Thomas Walle, U. Kristina Walle, George E. Lindenmayer, Karl John Karnaky, R. Kinne, Jiann‐Trzuo Lin, Rolf K. H. Kinne, Gregory L. Price, Gerhardt Pohl and Keith L. Davis and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Richard A. Walgren

62 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard A. Walgren United States 21 616 507 325 319 281 65 1.8k
Khuloud Bajbouj United Arab Emirates 23 866 1.4× 375 0.7× 208 0.6× 100 0.3× 71 0.3× 66 1.8k
Zhongzhou Shen United States 20 1.1k 1.7× 566 1.1× 104 0.3× 279 0.9× 74 0.3× 28 2.6k
Monika Fritzer‐Szekeres Austria 24 658 1.1× 257 0.5× 164 0.5× 111 0.3× 59 0.2× 74 1.7k
Haseeb Zubair United States 25 1.4k 2.3× 369 0.7× 204 0.6× 205 0.6× 53 0.2× 50 2.2k
Jyh‐Ming Chow Taiwan 25 903 1.5× 286 0.6× 149 0.5× 134 0.4× 45 0.2× 40 1.7k
Manfred Steiner United States 21 472 0.8× 120 0.2× 123 0.4× 272 0.9× 106 0.4× 59 1.9k
Siranoush Shahrzad Canada 12 616 1.0× 152 0.3× 132 0.4× 217 0.7× 85 0.3× 17 1.4k
Valeria Cucciolla Italy 18 643 1.0× 254 0.5× 99 0.3× 311 1.0× 54 0.2× 21 1.4k
Karol Kajo Slovakia 25 1.0k 1.7× 499 1.0× 202 0.6× 265 0.8× 36 0.1× 134 2.6k
Jie Liao United States 23 635 1.0× 206 0.4× 331 1.0× 167 0.5× 27 0.1× 37 1.6k

Countries citing papers authored by Richard A. Walgren

Since Specialization
Citations

This map shows the geographic impact of Richard A. Walgren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard A. Walgren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard A. Walgren more than expected).

Fields of papers citing papers by Richard A. Walgren

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard A. Walgren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard A. Walgren. The network helps show where Richard A. Walgren may publish in the future.

Co-authorship network of co-authors of Richard A. Walgren

This figure shows the co-authorship network connecting the top 25 collaborators of Richard A. Walgren. A scholar is included among the top collaborators of Richard A. Walgren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard A. Walgren. Richard A. Walgren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Gómez, Eliana B, Kevin Ebata, Mary S. Rosendahl, et al.. (2023). Pirtobrutinib preclinical characterization: a highly selective, non-covalent (reversible) BTK inhibitor. Blood. 142(1). 62–72. 56 indexed citations
3.
Taniguchi, Hiroya, Takayuki Yoshino, Kensei Yamaguchi, et al.. (2021). Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study. Current Medical Research and Opinion. 37(10). 1769–1778. 3 indexed citations
4.
Valle, Juan W., Li‐Yuan Bai, Р. В. Орлова, et al.. (2020). Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study.. Journal of Clinical Oncology. 38(4_suppl). 477–477. 23 indexed citations
5.
Palandri, Francesca, Maria R. Baer, Donald P. Quick, et al.. (2018). Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms. Leukemia Research. 71. 82–88. 41 indexed citations
6.
Verstovšek, Srđan, Ruben A. Mesa, Mohamed E. Salama, et al.. (2017). A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Leukemia Research. 61. 89–95. 31 indexed citations
7.
Petrylak, Daniel P., K.N. Chi, Alexandra Drakaki, et al.. (2017). RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma. Annals of Oncology. 28. v621–v621. 4 indexed citations
8.
Yan, S. Betty, Suzane L. Um, Victoria L. Peek, et al.. (2017). MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping. Investigational New Drugs. 36(4). 536–544. 33 indexed citations
9.
Petrylak, Daniel P., Manish Kohli, Andrew Eisen, et al.. (2015). 2508 Three-arm phase II randomized trial of docetaxel monotherapy or combined with ramucirumab or icrucumab in second-line locally advanced or metastatic urothelial carcinoma. European Journal of Cancer. 51. S476–S476. 3 indexed citations
10.
Wu, Wenjuan, Bi Chen, Kelly M. Credille, et al.. (2013). Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET. Clinical Cancer Research. 19(20). 5699–5710. 53 indexed citations
11.
Verstovšek, Srđan, Ruben A. Mesa, Celine Pitou, et al.. (2011). Phase I Study of the JAK2 V617F Inhibitor, LY2784544, in Patients with Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET). Blood. 118(21). 2814–2814. 29 indexed citations
12.
13.
Price, Gregory L., et al.. (2011). A Retrospective Observational Study of Annual Healthcare Costs for Patients with Forms of Myeloproliferative Neoplasms (MPN). Blood. 118(21). 2060–2060. 7 indexed citations
14.
Florensa, Lourdes, Beatríz Bellosillo, Leonor Arenillas, et al.. (2010). LY2784544, a Novel JAK2 Inhibitor, Decreases In Vitro Growth of Hematopoietic Human Progenitors From JAK2 V617F Positive Polycythemia Vera Patients. Blood. 116(21). 5054–5054. 3 indexed citations
15.
Skol, Andrew D., Richard A. Walgren, Jin Shao, et al.. (2009). Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood. 113(22). 5575–5582. 65 indexed citations
16.
Graubert, Timothy A., Jin Shao, Richard A. Walgren, et al.. (2009). Integrated Genomic Analysis Implicates Haploinsufficiency of Multiple Chromosome 5q31.2 Genes in De Novo Myelodysplastic Syndromes Pathogenesis. PLoS ONE. 4(2). e4583–e4583. 35 indexed citations
17.
Martin, Mike G., Richard A. Walgren, Geoffrey L. Uy, et al.. (2009). A phase II study of 5‐day intravenous azacitidine in patients with myelodysplastic syndromes. American Journal of Hematology. 84(9). 560–564. 32 indexed citations
18.
Walgren, Richard A., Michael A. Province, Howard L. McLeod, et al.. (2007). Identification of Polymorphisms Associated with Susceptibility to Therapy-Related MDS and AML.. Blood. 110(11). 15–15. 4 indexed citations
19.
Walgren, Richard A. & Howard L. McLeod. (2005). Small Inhibitory RNA – a Tool for Credentialing Candidate Genes. Pharmacogenomics. 6(3). 281–292. 1 indexed citations
20.
Walgren, Richard A., et al.. (2000). ナトリウム依存性グルコース輸送体SGLT1による食事性フラボノイド,クエルセチン4′-β-グルコシドの細胞内取り込み. Journal of Pharmacology and Experimental Therapeutics. 294(3). 837–843. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Khuloud Bajbouj Breakdown of academic impact, for papers by Zhongzhou Shen Breakdown of academic impact, for papers by Monika Fritzer‐Szekeres Breakdown of academic impact, for papers by Haseeb Zubair Breakdown of academic impact, for papers by Jyh‐Ming Chow Breakdown of academic impact, for papers by Manfred Steiner Breakdown of academic impact, for papers by Siranoush Shahrzad Breakdown of academic impact, for papers by Valeria Cucciolla Breakdown of academic impact, for papers by Karol Kajo Breakdown of academic impact, for papers by Jie Liao
Rankless by CCL
2026